AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth

Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics have announced promising results regarding the efficacy of TT-4, an A2B receptor antagonist, in treating human epithelioid mesothelioma, showing superior performance compared to anti-PD-1 therapy [1][2][3] Group 1: Research Findings - The abstract published indicates that A2B receptor inhibition leads to a reduction in adenosine-mediated PD-L1 expression in mesothelioma cells, which is associated with decreased CREB phosphorylation [1][2] - In vivo studies demonstrated that TT-4 monotherapy outperformed anti-PD-1, and the combination of TT-4 with anti-PD-1 exhibited significantly enhanced anti-tumor activity compared to either treatment alone, with increased T-cell infiltration observed [2][3] Group 2: Presentation Details - The findings will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 25, 2025, in Boston, Massachusetts [4] Group 3: Company Overview - AlphaTON Capital is focused on building a strategic reserve of TON tokens and developing the Telegram ecosystem, providing institutional-grade exposure to the TON ecosystem while maintaining governance standards of a Nasdaq-listed company [5][6] - Cyncado Therapeutics is developing small molecule adenosine receptor antagonists targeting A2A and A2B receptors, with TT-4 being the lead program aimed at overcoming immune suppression in oncology, particularly mesothelioma [8]